Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PhaseOut DMD
NCT02858362Phase 2Terminated
- Sponsor
- Summit Therapeutics
- Start
- Jun 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ezutromid in Duchenne muscular dystrophy (DMD), sponsored by Summit Therapeutics. Started Jun 2016; status: terminated.
02
Drugs
ezutromid
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02858362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858362.